AR078777A1 - Derivados de espirolactama y usos de los mismos - Google Patents

Derivados de espirolactama y usos de los mismos

Info

Publication number
AR078777A1
AR078777A1 ARP100103926A ARP100103926A AR078777A1 AR 078777 A1 AR078777 A1 AR 078777A1 AR P100103926 A ARP100103926 A AR P100103926A AR P100103926 A ARP100103926 A AR P100103926A AR 078777 A1 AR078777 A1 AR 078777A1
Authority
AR
Argentina
Prior art keywords
alkyl
3alkyl
cycloalkyl
halogen
heteroaryl
Prior art date
Application number
ARP100103926A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR078777A1 publication Critical patent/AR078777A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal farmacéuticamente aceptable de los mismos, y composiciones farmacéuticas y usos de los mismos para trastornos del S.N.C. Reivindicacion 1: Un compuesto de la formula (1): en donde: R1 y R2 son cada un independientemente arilo, heteroarilo, alquilo, cicloalquilo, cetocicloalquilo, o heterociclilo, que está opcionalmente mono-, di-, o tri-sustituido independientemente con alquilo, cicloalquilo, alcoxi, hidroxi, halogeno, ciano, trifluoroalquilo, amino, acilo, arilo, heteroarilo, heterociclilo, -C(O)NHR30, -C(O)N(R30)R31, -NHC(O)R30, -N(R30)C(O)R31, -NHR30, -N(R30)R31, o -OR30; en donde: R30 y R31 son cada uno independientemente alquiloC1-6 o cicloalquiloC1-6 que está opcionalmente sustituido con acilo, halogeno, -CN, -NH2, -NH(alquiloC1-3), -N(alquiloC1-3)2, alquilheterocicliloC1-3, alquilcarbamatoC1-3, -C(O)NH(alquiloC1-3), -C(O)N(alquiloC1-3)2, -NHC(O)-alquiloC1-3, -N(alquiloC1-3)-C(O)-alquiloC1-3, OH, o -O-alquiloC1-6 y cada sustituyente arilo, heteroarilo o heterociclilo está opcionalmente sustituido con alquiloC1-3, cicloalquiloC3-5, alcoxiC1-3, hidroxi, halogeno, ciano, trifluoroalquilo, o amino; R3, R4, R5 y R6 son cada uno independientemente H, alquiloC1-3, cicloalquiloC3-5, halogeno, o hidroxi; R7 es H; o R1 y R7 tomados juntos con el -C(O)N- al cual están unidos forman un heterocicloalquilo de 4- a 12 miembros mono- o bicíclico o heteroarilo, que opcionalmente contiene 1-3 heteroátomos adicionales; o una sal farmacéuticamente aceptable de los mismos.
ARP100103926A 2009-10-28 2010-10-26 Derivados de espirolactama y usos de los mismos AR078777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25583709P 2009-10-28 2009-10-28

Publications (1)

Publication Number Publication Date
AR078777A1 true AR078777A1 (es) 2011-11-30

Family

ID=43898951

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103926A AR078777A1 (es) 2009-10-28 2010-10-26 Derivados de espirolactama y usos de los mismos

Country Status (24)

Country Link
US (2) US8633190B2 (es)
EP (1) EP2493304B1 (es)
JP (1) JP5840133B2 (es)
KR (1) KR20130027447A (es)
CN (1) CN102595893B (es)
AR (1) AR078777A1 (es)
AU (1) AU2010313550A1 (es)
BR (1) BR112012009861A2 (es)
CA (1) CA2777033A1 (es)
CL (1) CL2012001092A1 (es)
CO (1) CO6531479A2 (es)
CR (1) CR20120146A (es)
DO (1) DOP2012000078A (es)
EA (1) EA201290229A1 (es)
ES (1) ES2465994T3 (es)
HK (1) HK1173339A1 (es)
IL (1) IL218682A0 (es)
MA (1) MA33760B1 (es)
MX (1) MX2012004835A (es)
NZ (1) NZ598912A (es)
TN (1) TN2012000105A1 (es)
TW (1) TW201118069A (es)
WO (1) WO2011053575A1 (es)
ZA (1) ZA201203076B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8424677B2 (en) 2010-10-29 2013-04-23 Graphic Packaging International, Inc. Carton with retention features
US10287073B2 (en) 2014-06-10 2019-05-14 Graphic Packaging International, Llc Carton with tamper resistant features
USD972943S1 (en) 2020-07-14 2022-12-20 Graphic Packaging International, Llc Carrier
US11981489B2 (en) 2020-05-29 2024-05-14 Graphic Packaging International, Llc Carrier with container retention features

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463013A (en) * 1982-04-09 1984-07-31 The Upjohn Company Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
GB9613969D0 (en) * 1996-07-03 1996-09-04 Merck Sharp & Dohme Therapeutic agents
US7989624B2 (en) * 2004-09-09 2011-08-02 Merck Sharp & Dohme Corp. Aryl spirolactam CGRP receptor antagonists
US20090069340A1 (en) 2004-12-27 2009-03-12 Astrazeneca Ab Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
WO2007127763A2 (en) * 2006-04-25 2007-11-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101511802A (zh) * 2006-09-13 2009-08-19 阿斯利康(瑞典)有限公司 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8424677B2 (en) 2010-10-29 2013-04-23 Graphic Packaging International, Inc. Carton with retention features
US10287073B2 (en) 2014-06-10 2019-05-14 Graphic Packaging International, Llc Carton with tamper resistant features
US11981489B2 (en) 2020-05-29 2024-05-14 Graphic Packaging International, Llc Carrier with container retention features
USD972943S1 (en) 2020-07-14 2022-12-20 Graphic Packaging International, Llc Carrier

Also Published As

Publication number Publication date
MX2012004835A (es) 2012-05-29
JP5840133B2 (ja) 2016-01-06
EP2493304A1 (en) 2012-09-05
JP2013509416A (ja) 2013-03-14
AU2010313550A1 (en) 2012-04-12
WO2011053575A1 (en) 2011-05-05
TN2012000105A1 (en) 2013-09-19
US20110098299A1 (en) 2011-04-28
EP2493304B1 (en) 2014-02-26
DOP2012000078A (es) 2012-06-30
US9359297B2 (en) 2016-06-07
CN102595893B (zh) 2014-12-31
ES2465994T3 (es) 2014-06-09
EA201290229A1 (ru) 2012-08-30
EP2493304A4 (en) 2013-04-24
IL218682A0 (en) 2012-05-31
US8633190B2 (en) 2014-01-21
TW201118069A (en) 2011-06-01
CL2012001092A1 (es) 2012-10-05
NZ598912A (en) 2013-08-30
CO6531479A2 (es) 2012-09-28
CA2777033A1 (en) 2011-05-05
US20140194424A1 (en) 2014-07-10
KR20130027447A (ko) 2013-03-15
CN102595893A (zh) 2012-07-18
CR20120146A (es) 2012-06-26
ZA201203076B (en) 2013-06-26
MA33760B1 (fr) 2012-11-01
BR112012009861A2 (pt) 2015-09-29
HK1173339A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
AR078777A1 (es) Derivados de espirolactama y usos de los mismos
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
AR084408A1 (es) Compuestos de purina y 7-deazapurina substituidos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
ES2722048T3 (es) Compuestos de triazolopirimidina y usos de los mismos
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR072913A1 (es) Naftiridinas sustituidas y su utilizacion como medicamento
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR078408A1 (es) Derivados de indol como moduladores de los crac
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR072839A1 (es) Derivados adamantil diamida y usos de los mismos
AR068466A1 (es) Cianoisoquinolina
AR093184A1 (es) Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden
CU23706B7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal